Skip to main content
. 2021 Apr 12;60(19):3143–3147. doi: 10.2169/internalmedicine.6577-20

Figure 3.

Figure 3.

Clinical course after the development of dyspnea (from day 6 to day 29). After the initiation of SMX/TMP treatment and adjunctive corticosteroid therapy, the patient’s clinical condition and radiographic findings gradually improved. MCFG: micafungin, mPSL: methylprednisolone, PSL: prednisolone, SMX/TMP: trimethoprim/sulfamethoxazole, TAZ/PIPC: tazobactam/piperacillin